Zacks Investment Research downgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to Hold in a report released today.
- Updated: October 7, 2016
Zacks Investment Research has downgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to Hold in a report released on 10/7/2016.
Previously on Tuesday October 04, 2016, Zacks Investment Research released a statement about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) increased the target price from $0.00 to $9.25. At the time, this indicated a possible upside of 0.17%.
Only yesterday Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) traded -1.91% lower at $7.88. ACHN’s 50-day average is $8.28 and its two hundred day moving average is $8.46. The last closing price is down -8.75% relative to the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Volume of trade was down over the average, with 578,776 shares of ACHN changing hands under the typical 1,440,230
With a total market value of $0, Achillion Pharmaceuticals, Inc. has PE ratio of 157.55 with a 52 week low of $5.57 and a 52 week high of $10.95 .
Also covering Achillion Pharmaceuticals, Inc.'s stock price target, a total of 5 brokers have issued a ratings update on the company. The average target price is $9.40 with 2 analysts rating the company a strong buy, one equity analyst rating the company a buy, three firms rating the stock a hold, 1 equity analyst rating the company a underperform, and lastly 0 firms rating the company a sell.
More About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.